Evidence map›Paper›PMID 35850421›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2022

A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection.

Santa-Mariela Olivera-Ugarte, Marilène Bolduc, Marie-Ève Laliberté-Gagné, Léa-Jeanne Blanchette, Caroline Garneau, Maude Fillion, Pierre Savard, Isabelle Dubuc, Louis Flamand, Omar Farnòs and 8 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Chemical reviews · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Santa-Mariela Olivera-UgarteDepartment of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
Marilène BolducDepartment of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
Marie-Ève Laliberté-GagnéDepartment of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
Léa-Jeanne BlanchetteDepartment of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
Caroline GarneauDepartment of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
Maude FillionDepartment of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
Pierre SavardNeurosciences, Laval University, 2705 boulevard Laurier, Québec City, QC G1V 4G2, Canada.
Isabelle DubucDepartment of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
Louis FlamandDepartment of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
Omar FarnòsViral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montréal, QC H3A 0E9, Canada.
Xingge XuViral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montréal, QC H3A 0E9, Canada.
Amine KamenViral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montréal, QC H3A 0E9, Canada.
Mégan GilbertDepartment of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
Henintsoa RabezanaharyDepartment of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
Martina ScarroneDepartment of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
Christian CoutureQuebec Heart and Lung Institute-Laval University, Department of Anatomic Pathology and Cytology, Québec City, QC G1V 4G5, Canada.
Mariana BazDepartment of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
Denis LeclercDepartment of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada. Electronic address: Denis.Leclerc@crchudequebec.ulaval.ca.
Université Laval · CAWilfrid Laurier University · CAMcGill University · CA

Funding

CIHR 440390
6 · The paper itself

Abstract

A vaccine candidate to SARS-CoV-2 was constructed by coupling the viral receptor binding domain (RBD) to the surface of the papaya mosaic virus (PapMV) nanoparticle (nano) to generate the RBD-PapMV vaccine. Immunization of mice with the coupled RBD-PapMV vaccine enhanced the antibody titers and the T-cell mediated immune response directed to the RBD antigen as compared to immunization with the non-coupled vaccine formulation (RBD + PapMV nano). Anti-RBD antibodies, generated in vaccinated animals, neutralized SARS-CoV-2 infection in vitro against the ancestral, Delta and the Omicron variants. At last, immunization of mice susceptible to the infection by SARS-CoV-2 (K18-hACE2 transgenic mice) with the RBD-PapMV vaccine induced protection to the ancestral SARS-CoV-2 infectious challenge. The induction of the broad neutralization against SARS-CoV-2 variants induced by the RBD-PapMV vaccine demonstrate the potential of the PapMV vaccine platform in the development of efficient vaccines against viral respiratory infections.

Indexed as

COVID-19NanoparticlesAnimalsAntibodies, NeutralizingAntibodies, ViralBroadly Neutralizing AntibodiesCOVID-19 VaccinesHumansMiceMice, Inbred BALB CPotexvirusSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralBroadly Neutralizing AntibodiesCOVID-19 VaccinesPapaya mosaic virus (PapMV)Receptor binding domain (RBD), Sortase (SrtA), broad protectionRod-shaped nanoparticleSARS-CoV-2Vaccine platform

Identifiers

PMID35850421
PMCPMC9287509
OpenAlexW4285600541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.